Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin Inhaled Solution in Preventing RSV Pneumonia in BMT Recipients
NCT00016081Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 1998
- Primary completion
- Mar 2003
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ribavirin in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Progression of upper respiratory tract RSV infection to pneumonia at 28 days. Started Mar 1998; status: completed.
02
Drugs
ribavirin
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00016081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016081.